Author | Published year | Study ID | Number of patients | Age | Male (%) | Current smoker (%) | Ethnicity (%) | Mean post-BDR FEV1, % | GOLD stage | Previous exacerbation | Symptom | Intervention (LAMA/LABA) | Control | Treatment duration | Inhalation device |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aaron et al. | 2007 | ISRCTN29870041 | 449 | 67.7 | 56.4 | 27.9 | White: 98.2% | 41.8 | II–IV |  ≥ 1 | – | Tiotropium Handihaler/Salmeterol | 1) Fluticasone/Tiotropium Handihaler/Salmeterol 2) Tiotropium Handihaler | 52 weeks | DPI |
Asai et al. | 2013 | NCT01285492 | 158 | 69.3 | 95.6 | – | – | – | II–III | – | – | Glycopyrrolate/Indacaterol | Tiotropium Handihaler | 52 weeks | DPI |
Dahl et al. | 2013 | NCT01120717 | 338 | 62.6 | 76.9 | 45.2 | Caucasian: 80.5% Asian: 19.5% | 57.4 | II–III | – | – | Glycopyrrolate/Indacaterol | Placebo | 52 weeks | DPI |
Wedzicha et al. | 2013 | NCT01120691 | 2206 | 63.3 | 74.8 | 37.6 | White: 82.0% Asian: 11.7% | 37.2 | III–IV |  ≥ 1 | – | Glycopyrrolate/Indacaterol | 1) Glycopyrrolate 2) Tiotropium Handihaler | 64 weeks | DPI |
Donohue et al. | 2014 | NCT01316887 | 562 | 61.3 | 66.6 | – | Non-hispanic: 92.8% | 54.7 | II–III | – | – | Umeclidinium/Vilanterol | 1) Placebo 2) Umeclidinium | 52 weeks | DPI |
Buhl et al. | 2015 | NCT01431274 NCT01431287 | 5162 | 64 | 72.9 | 37 | – | 50 | II–IV | – | – | Tiotropium Respimat/Olodaterol | 1) Olodaterol 2) Tiotropium Respimat | 52 weeks | SMI |
Larbig et al. | 2015 | NCT01610037 | 812 | 64.4 | 72.4 | – | – | – | II–III | – | – | Glycopyrrolate/Indacaterol | 1) Placebo 2) Tiotropium Handihaler | 52 weeks | DPI |
Donohue et al. | 2016 | NCT01437540 | 590 | 64.2 | 55.1 | 45.9 | White: 92.4% | 51.4 | II–III | – | – | Aclidinium/Formoterol | Formoterol | 52 weeks | DPI |
Ferguson et al. | 2016 | NCT01682863 | 615 | 63.6 | 65.6 | 50.9 | White: 97.7% | 54.4 | II–III | – | mMRC ≥ 2 | Glycopyrrolate/Indacaterol | Indacaterol | 52 weeks | DPI |
Wedzicha et al. | 2016 | NCT01782326 | 3358 | 64.5 | 76 | 39.7 | – | 44.1 | II–III |  ≥ 1 | mMRC ≥ 2 | Glycopyrrolate/Indacaterol | Fluticasone/Salmeterol | 52 weeks | DPI |
D'Urzo et al.b | 2017 | NCT01572792 | 1669 | 64 | 53.1 | 51.5 | White: 93.2% | 53.5 | II–III | – | – | Aclidinium/Formoterol | 1) Formoterol 2) Placebo | 52 weeks | DPI |
Hanania et al. | 2017 | NCT01970878 | 3257 | 62.8 | 55.8 | 53.8 | – | 43.0a | II–IV | – | – | Glycopyrrolate/Formoterol | 1) Formoterol 2) Glycopyrrolate 3) Tiotropium Handihaler | 52 weeks | MDI |
Ichinose et al. | 2017 | NCT01536262 | 122 | 69.8 | 95.9 | 27.9 | – | 57.5 | II–IV | – | – | Tiotropium Respimat/Olodaterol | Olodaterol | 52 weeks | SMI |
Calverley et al. | 2018 | NCT02296138 | 7880 | 66.4 | 71.5 | 37 | White: 79.5% Asian: 14.5% | 44.5 | II–IV |  ≥ 1 | – | Tiotropium Respimat/Olodaterol | Tiotropium Respimat | 52 weeks | SMI |
Lipson et al. | 2018 | NCT02164513 | 10,355 | 65.3 | 66.4 | 34.6 | White: 78.2% Asian: 16.0% | 45.6 | II–IV |  ≥ 1 | CAT ≥ 10 | Umeclidinium/Vilanterol | 1) Fluticasone/Umeclidinium/Vilanterol 2) Fluticasone/Vilanterol | 52 weeks | DPI |
Papi et al. | 2018 | NCT02579850 | 1532 | 64.5 | 72 | 44.5 | – | 36.4 | III–IV |  ≥ 1 | CAT ≥ 10 | Glycopyrrolate/Indacaterol | Beclometasone/Glycopyrrolate/Formoterol | 52 weeks | DPI |